- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Introducing "Not So Different: a Podcast From The Center for Biosimilars"
In this innaugural episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.
The introduction of biosimilars into the US marketplace has been cause for both excitement and concern, as these products hold the potential to drive down costs and increase patient access, but face significant challenges to uptake. One of those challenges is interchangeability.
Federal law provides for interchangeable biosimilars, but the FDA has not yet granted that status to any biosimilar product, and hasn’t finalized its guidance on demonstrating interchangeability with a reference product. In this episode of "Not So Different," you’ll hear expert viewpoints on the issue of interchangeability from stakeholders across the biosimilars landscape.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
